Press Releases - Oncology

Press Releases - Oncology

April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing. 
February 9, 2016
Quanterix announces that Analytical Chemistry, a leading peer-reviewed scientific journal, has published a truly groundbreaking new study authored by Dr. David Walt of Tufts University that prominently features Quanterix’s Single Molecule Array Detection technology, Simoa.     
CAMBRIDGE, MA – October 13, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth–…
CAMBRIDGE, MA – November 2, 2010 – Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP…
DENVER – A new test could reliably detect early increases in prostate specific antigen (PSA) levels – a biomarker commonly used to measure the recurrence of prostate cancer – in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with…
CAMBRIDGE, MA – May 23, 2010 – Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company’s proprietary technology that demonstrates an unprecedented sensitivity…